SecBot SecBot
8-K ·Filed May 26, 2026

OLMA

Olema Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-237832
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This collaboration with Bayer provides external validation for OP-3136 and expands its potential into prostate cancer, a large market. The upcoming ASCO data readout on May 30, 2026, for the Phase 1 monotherapy study is a key near-term catalyst. Monitor for initial safety and efficacy data from the Phase 1 study, which will inform the probability of success for the broader OP-3136 program.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.55
T+0 close · May 26, 2026 · via day close
Latest settled
−16.53%
T+60 · $11.31
Vs SPY
−19.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $13.55entry
  2. T+1 · 6mo ago −4.72%α −4.74% · $12.91
  3. T+5 · 6mo ago −6.20%α −7.28% · $12.71
  4. T+20 · 5mo ago −15.42%α −13.48% · $11.46
  5. T+60 · 3mo ago −16.53%α −19.26% · $11.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor, OP-3136, in combination with Bayer's NUBEQA (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer (mCRPC). The study is expected to initiate in H2 2026, with Bayer supplying darolutamide and Olema leading the study. Olema retains full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136, providing validation and potential expansion into a new indication beyond breast cancer.

Key Facts

  • Olema entered a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 (KAT6 inhibitor) in combination with NUBEQA (darolutamide) in mCRPC.
  • Phase 1b/2 study will enroll approximately 36 patients with mCRPC; expected to initiate in H2 2026.
  • Bayer will supply darolutamide; Olema will lead the study and retain full global commercial and marketing rights to OP-3136.
  • This is the first clinical collaboration for OP-3136, which is currently in a Phase 1 monotherapy study and being evaluated in combination with fulvestrant and palazestrant in ER+/HER2- metastatic breast cancer.
  • Initial clinical data from the Phase 1 study of OP-3136 will be presented at ASCO on May 30, 2026.

Financial Impact

No financial terms disclosed; Bayer supplies drug, Olema retains full commercial rights to OP-3136.

pipeline valuecommercial rights

Risk Factors

  • Phase 1b/2 study is early-stage and may not demonstrate sufficient efficacy or safety.
  • No financial terms disclosed; the collaboration does not provide immediate funding or milestone payments.
  • OP-3136 is still in early clinical development; the ASCO data may be mixed or underwhelming.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-237832
Document: olma-ex99_1.htm0001193125-26-237832
Document: 0001193125-26-237832-index-headers.html0001193125-26-237832
Document: 0001193125-26-237832-index.html0001193125-26-237832
Document: 0001193125-26-237832.txt0001193125-26-237832

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026